Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Clinical Drug Investigation|August 26, 2018
Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based StudyDaniel R Morales, Jim Slattery, Luis Pinheiro, et al.
European Journal of Clinical Pharmacology|January 25, 2019
Prescribing patterns of tramadol in adults in IMS® primary care databases in France and Germany between 1 January 2006 and 30 June 2016Karin Hedenmalm, Jim Slattery, Izabela Skibicka-Stepien, et al.
Clinical Pharmacology and Therapeutics|January 21, 2020
Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model?: A Validation Study Based on Prescribing Codeine in ChildrenGianmario Candore, Karin Hedenmalm, Jim Slattery, et al.
Drug Safety|July 17, 2021
Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident UsersKarin Hedenmalm, Alexandra Pacurariu, Jim Slattery, et al.
JAMA Neurology|April 30, 2019
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate TherapyDaniel Morales, Alexandra Pacurariu, Jim Slattery, et al.
Vaccine|April 20, 2011
Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilanceXavier Kurz, François Domergue, Jim Slattery, et al.
Clinical Drug Investigation|November 23, 2018
Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control StudyDaniel R Morales, Jim Slattery, Alexandra Pacurariu, et al.
Pharmacoepidemiology and Drug Safety|November 16, 2020
Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance dataAndrej Segec, Jim Slattery, Daniel R Morales, et al.
Clinical Drug Investigation|February 7, 2019
Correction to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control StudyDaniel R Morales, Jim Slattery, Alexandra Pacurariu, et al.
Pharmacoepidemiology and Drug Safety|October 25, 2020
What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?Justina Januskiene, Andrej Segec, Jim Slattery, et al.
Pageof 4